The global fluorine-18 industry was valued at USD 1.9 billion in 2024 and is projected to surpass USD 3.2 billion by the end of 2035, growing at a CAGR of 4.8% from 2025 to 2035. This growth is driven by increasing demand for advanced diagnostic imaging, particularly in nuclear medicine, along with rising adoption of PET scans and ongoing advancements in radiopharmaceutical production technologies.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=82266

Market Overview

Fluorine-18 (F-18) is a positron-emitting fluorine isotope with unstable nature as the first choice for different applications in PET and nuclear medicine. F-18 is a positron-emitting radionuclide with a physical half-life of approximately 110 minutes. F-18 can be applied when precise positron emission tomography (PET) is needed.

The production of F-18 implies using a cyclotron by proton irradiation of oxygen-18-enriched water. It is mainly due to its perfect decay pattern and relatively short half-life that F-18 keeps being a leading figure in life science research and diagnostic imaging.

Analysts’ Viewpoint on the Global Fluorine-18 Market

The fluorine-18 market is driven by the ongoing development of cyclotron facilities and advancements in radiochemistry. Production technologies have improved the efficiency and availability of fluorine-18, thereby making it more accessible for medical applications.

The clinical adoption gets accelerated by increased reimbursement coverage for PET procedures with F-18 tracers, improved GMP guidelines, and faster lot-release procedures. Moreover, the service providers are increasingly adopting remote monitoring and preventive maintenance measures in order to minimize the downtime and improve the delivery of tracers, which are time-sensitive and have a half-life of approximately 110 minutes.

The other critical drivers of the market include the chemistry and workflow advancements. Production times are reduced by automated synthesis modules, modular cassette kits, and microfluidic reactors, and reproducible, multi-tracer operations on a single line, thereby optimizing asset utilization.

Analysis of Key Players in the Fluorine-18 Market

The landscape is a mix of global medical technology giants and specialized radiopharmaceutical manufacturers.

Leading companies operating in the global market include:

• Lantheus Holdings, Inc.
• Siemens Healthineers AG
• Curium Austria GmbH
• GE HealthCare
• Blue Earth Diagnostics
• China lsotope & Radiation Corporation
• Eli Lilly and Company
• Yantai Dongcheng Pharmaceutical Group Co., Ltd.
• Advanced Accelerator Applications SA
• Telix Pharmaceuticals Limited
• SOFIE Co.
• Cardinal Health
• Life Molecular Imaging
• IBA Radiopharma Solutions
• GNC India
• ECKERT & ZIEGLER

These players are focusing on strategic partnerships with hospitals to provide “dose-on-demand” services, ensuring a reliable supply of isotopes despite their rapid decay.

Recent Developments in the Fluorine-18 Market

• In June 2025, Eli Lilly and Company revealed that the United States Food and Drug Administration had given a green light to the label update for Amyvid (florbetapir F 18 injection) for intravenous use.
• In September 2024, GE HealthCare announced that the U.S. Food and Drug Administration (FDA) had approved Flyrcado (flurpiridaz F 18) injection, a PET MPI novel agent for the non-invasive detection of coronary artery disease (CAD).

👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82266

Key Market Trends & Strategies

🩺 The Rise of Theranostics

• Diagnostic-Therapeutic Pairing: F-18 is increasingly used as the “diagnostic half” of theranostic pairs (e.g., using F-18 PSMA to identify tumors before treating them with Lutetium-177).
• Personalized Dosimetry: Using F-18 scans to calculate the exact radiation dose needed for targeted isotope therapy.

📈 Market Challenges

• Logistical Constraints: The 110-minute half-life remains a barrier for rural or remote regions without immediate access to a cyclotron facility.
• High Infrastructure Costs: Establishing a PET/CT facility with an integrated cyclotron typically requires an investment of US$ 5 Mn to US$ 7 Mn.

🌟 Growth Opportunities

• Neurological Imaging: Growing use of F-18 tracers for early diagnosis of Parkinson’s and Alzheimer’s diseases as new disease-modifying therapies enter the market.
• Cardiology Expansion: The move toward PET MPI over traditional SPECT imaging due to superior resolution and lower patient radiation exposure.

Market Segmentation

By Type (Tracer)

• FDG (Fluorodeoxyglucose)
• NaF (Sodium Fluoride)
• FLT (Fluorothymidine)
• Novel Tracers (PSMA, F-DOPA)

By Therapeutic Area

• Oncology (Largest Share)
• Cardiology (Fastest Growing)
• Neurology
• Others

By End-User

• Hospitals
• Diagnostic Imaging Centers
• Academic & Research Institutes

Regional Outlook

• North America: The dominant market (~37% share in 2024). Growth is sustained by high PET/CT installation rates and favorable reimbursement for novel F-18 tracers.
• Asia-Pacific: Anticipated to be the fastest-growing region. China and India are aggressively expanding their nuclear medicine infrastructure to address rising cancer incidences.
• Europe: Focuses on regulatory harmonization and the adoption of PET/MRI systems for pediatric and high-precision oncology.

Conclusion

The Fluorine-18 market is evolving from a single-product industry (FDG) into a diverse ecosystem of specialized tracers. As global healthcare shifts toward precision oncology and early-stage neurological intervention, the demand for F-18 will only intensify. The key to long-term market dominance will lie in the decentralization of production through compact cyclotrons and the successful commercialization of non-oncology tracers.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=82266&ltype=S

FAQs

• How big was the global fluorine-18 market in 2024?

The global fluorine-18 market was valued at US$ 1.9 Bn in 2024

• How big will the global fluorine-18 industry be in 2035?

The global fluorine-18 industry is projected to reach more than US$ 3.2 Bn by the end of 2035

• What are the factors driving the fluorine-18 market?

Increasing prevalence of chronic diseases, particularly cancer, advancements in medical imaging technologies, innovations in radiopharmaceutical production and favourable regulatory environments are some of the factors driving the expansion of fluorine-18 market.

• What will be the CAGR of the global fluorine-18 industry during the forecast period?

The CAGR is anticipated to be 4.8% from 2025 to 2035

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com